prof. dr. Piet Ost
- ORCID iD
-
0000-0002-2203-4848
Show
Sort by
-
- Journal Article
- A1
- open access
Transcriptomic and clinical heterogeneity of metastatic disease timing within metastatic castration-sensitive prostate cancer
-
- Journal Article
- A1
- open access
Clinical and genomic differences between advanced molecular imaging-detected and conventional imaging-detected metachronous oligometastatic castration-sensitive prostate cancer
-
PEACE V—Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM) : acute toxicity of a randomized phase 2 trial
-
WNT pathway mutations in metachronous oligometastatic castration-sensitive prostate cancer
-
- Journal Article
- A1
- open access
Whole slide imaging-based prediction of TP53 mutations identifies an aggressive disease phenotype in prostate cancer
-
Checkpoint inhibitors in combination with stereotactic body radiotherapy in patients with advanced solid tumors : the CHEERS phase 2 randomized clinical trial
-
Metastases-directed stereotactic body radiotherapy in combination with targeted therapy or immunotherapy : systematic review and consensus recommendations by the EORTC–ESTRO OligoCare consortium
-
- Journal Article
- A1
- open access
Accuracy and reliability of a commercial treatment planning system in nontarget regions in modern prostate radiotherapy
-
Experiences of men with prostate cancer participating in a clinical pathway with a supervised group-based exercise program to combat androgen deprivation-induced side effects : a qualitative focus group study
-
- Journal Article
- A1
- open access
Evaluating the impact of prostate only versus pelvic radiotherapy for pathological node-positive prostate cancer : first results from the multicenter phase 3 PROPER trial